144
Participants
Start Date
May 1, 2017
Primary Completion Date
May 23, 2021
Study Completion Date
June 23, 2021
Fidaxomicin
Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
Vancomycin
Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
University of Michigan, Ann Arbor
St. Joseph Mercy Hospital, Ypsilanti
Merck Sharp & Dohme LLC
INDUSTRY
University of Michigan
OTHER